WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 31-July-2017 (data as of 19-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 2'3701 Infant (under 12 months) mortality rate: 272
GDP / capita (US$): 8'0771 Child (under 5 years) mortality rate: 332

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 798  787  776  765  753  573  537  409 
Births 14  15  15  15  15  16  20  18 
Surviving infants 14  14  14  14  14  15  19  16 
Pop. less than 5 years 70  71  71  72  73  78  92  73 
Pop. less than 15 years 215  216  217  219  220  237  236  180 
Female 15-49 years 217  213  210  205  201  136  119  90 

Number of reported cases

(Click for retrospective incidence data for Bhutan)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
  27 
Measles
ChartChart ChartChart
  45  11  418  173  1'642 
Mumps
ChartChart
  795  620  206  20  198  1'967 
Pertussis
ChartChart
  12  18  464 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Bhutan)
Vaccine year result method % card seen                                                
BCG 2011  100     91  99*  99*  99*  97  95  97  87  43 
DTP1 2011  100     91  99  99*  99*  97  97  99 
DTP3 2011  99     91  98  99  99  97  97  92  84 
DTP4         
IPV1          98  43 
HepB_BD          82  78  78  64  60 
HepB3 2011  99     91  98  99  99  97  97  98 
Hib3          98  99  97  97 
JapEnc         
MCV1          97  97  97  94  95  79  21 
MCV2          90  94  92  89  90 
MenA         
PCV1         
PCV2         
PCV3         
Pol3 2011  97     91  97  98  98  97  97  98  84 
Rota1         
RotaC         
RCV1          97  93  97  94  95 
TT2plus 2007  97  EPI   98  85  91  93  39  79  76  63 
PAB          96  79 
VAD1          91  82  97  44 
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Bhutan)
BCG
ChartChart
  99  99  99  97  95  97  99  43 
DTP1
ChartChart
  99  99  99  97  97  96  98  25 
DTP3
ChartChart
  98  99  99  97  97  92  96 
HepB3
ChartChart
  98  99  99  97  97  98 
HepB_BD
ChartChart
  82  78  78  64  60 
Hib3
ChartChart
  98  99  99  97  97 
IPV1
  90  43 
MCV1
ChartChart
  97  97  97  94  95  78  93  21 
MCV2
ChartChart
  90  94  92  89  90 
PCV3
 
Pol3
ChartChart
  97  98  98  97  97  98  96 
RCV1
ChartChart
  97  97  97  94  95 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 20  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 95
From 80 to 89% 5
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwP 24 months; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HepB Birth; Yes within 24 hours
HPV 12 years; +2, +6 months; Yes Grade 6 girls
IPV 14 weeks; Yes
MMR 9, 24 months; Yes
OPV birth; 6, 10, 14 weeks; Yes
Td 6, 12 years; Yes
VitaminA 6, 12, 18, 24, 30 months; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2014-2018  2014-2018  2013-2018  2'013  2'013  2009-2013 
Nº of districts with microplans that include activities to raise immunization coverage number 20  20  20  20  20  20  20 

System performance

Total Nº districts in country number 20    20  20  20  20  20 
Nº districts with DTP3 coverage >=80% number 20  20  20  20  19  19  18 
% of districts with DTP3 coverage >=80% From 0 to 100% 100    100  100  95  95  90 
Nº districts with measles (MCV1) coverage >=95% number 15  15  11  13 
% of districts with MCV1 coverage >=95% From 0 to 100% 75    55  45  40  40  65 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 25  43  31         

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.